Company intelligence / Profile preview
Incyte
Wilmington, Delaware, United States
- Ownership
- Public · INCY
- Employees
- ~2500
- Development stage
- Commercial
01
Overview
Incyte has multiple approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease, and Opzelura (ruxolitinib cream) for vitiligo and eczema. The company recently reported positive topline results from Phase 3 trials of povorcitinib in hidradenitis suppurativa and is conducting Phase 2 trials in vitiligo.
- Therapeutic areas
- GastroenterologyOncologyImmunologyDermatology
- Modalities
- Small moleculesmonoclonal antibodiesbispecific antibodies
- Industry
- Biotech
02
Drug pipeline
61 assets60 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $25.5B
- Total revenue
- $1.7B
- Enterprise value
- $21B
Beyond the preview
Go deeper on Incyte.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Incyte.